Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

In 1997, Johnson was appointed to Miami-Dade Circuit Court, where he established the first Juvenile Drug Court in the county, ...

Abnormal cells can clog blood vessels, leading to severe pain episodes and restricting oxygen delivery to vital organs ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...